Multicellular living organisms and unmodified parts thereof and – Nonhuman animal – Transgenic nonhuman animal
Reexamination Certificate
2006-12-20
2009-10-27
Crouch, Deborah (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Nonhuman animal
Transgenic nonhuman animal
C800S003000, C800S012000
Reexamination Certificate
active
07608749
ABSTRACT:
The invention provides transgenic non-human animals and transgenic non-human mammalian cells harboring a transgene encoding an APP polypeptide comprising the Swedish mutation.
REFERENCES:
patent: 4666829 (1987-05-01), Glenner et al.
patent: 4736866 (1988-04-01), Leder et al.
patent: 4873191 (1989-10-01), Wagner et al.
patent: 5134062 (1992-07-01), Blass
patent: 5200339 (1993-04-01), Abraham
patent: 5221607 (1993-06-01), Cordell et al.
patent: 5234814 (1993-08-01), Card et al.
patent: 5387742 (1995-02-01), Cordell
patent: 5441870 (1995-08-01), Seubert et al.
patent: 5455169 (1995-10-01), Mullan
patent: 5547841 (1996-08-01), Marotta et al.
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5604102 (1997-02-01), McConlogue et al.
patent: 5605811 (1997-02-01), Seubert et al.
patent: 5612486 (1997-03-01), McConlogue et al.
patent: 5721130 (1998-02-01), Seubert et al.
patent: 5750349 (1998-05-01), Suzuki et al.
patent: 5766846 (1998-06-01), Schlossmacher et al.
patent: 5837672 (1998-11-01), Schenk et al.
patent: 5580003 (1998-12-01), McConlogue et al.
patent: 5850003 (1998-12-01), McLonlogue et al.
patent: 5955317 (1999-09-01), Suzuki et al.
patent: 6018024 (2000-01-01), Seubert et al.
patent: 6245964 (2001-06-01), McLonlogue et al.
patent: 6586656 (2003-07-01), McLonlogue et al.
patent: 123 527 (1984-10-01), None
patent: 173 494 (1986-03-01), None
patent: 171 496 (1991-11-01), None
patent: 184 187 (1992-06-01), None
patent: 444 856 (1997-09-01), None
patent: 87-100291 (1987-05-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 87/02671 (1987-05-01), None
patent: WO 90/12870 (1990-11-01), None
patent: WO 90/12871 (1990-11-01), None
patent: WO 91/16628 (1991-10-01), None
patent: WO 91/19810 (1991-12-01), None
patent: WO 92/00521 (1992-01-01), None
patent: WO 92/09699 (1992-06-01), None
patent: WO 92/13069 (1992-08-01), None
patent: WO 93/01817 (1993-03-01), None
patent: WO 93/21526 (1993-10-01), None
patent: WO 93/14200 (1993-12-01), None
patent: WO 94/00569 (1994-01-01), None
patent: WO 94/01772 (1994-01-01), None
patent: WO 94/23049 (1994-10-01), None
Moreadith et al. Gene Targeting in Embryonic Stem Cell: the New Physiology and Metabolism. J. Molec. Med. 1997, vol. 75, 208-216.
Seamark, R. F. Progress and Emerging Problems in Livestock Transgenesis: a Summary Perspective. Reproduct. Fertil. DEvel.. 1994, vol. 6, pp. 653-657.
Mullins et al. Perspective Series: Molecular Medicine in Genetically Engineered Animals, Transgenesis in the Rat and Larger Mammals. J. Clinical INvest. vol. 98, No. 11, Supp. 1996, pp. 537-540.
Podlisny e al. Synthetic Amyloid Beta Protein Fails to Produce specific Neurotozicity in Monkey Cerebral Cortex. Neuro. Biol. Aging. 1992, vol. 13, pp. 561-567.
Lannfelt et al. Alzheimer's Disease: Molecular Genetics and Transgenic Animal Models. Behav. Brain Res., 1993, vol. 57, pp. 207-213.
Felsenstein et al. Transgenic Rat and In-Vitro Studies of β-Amyloid Precursor Protein Processing. Hanin, I. et al., eds., Advances in Behavioral Biology: Alzheimer's and Parkinson's diseases: Recent developments. Publisher: Plenum Press, 1995, pp. 401-405.
Quon et al. Formation of β-Amyloid Deposits in Brains of Transgenic Mice. Nature. 1991, vol. 352, pp. 239-241.
“Alzheimer's Assult,”ScienceScope, p. 1059 (Feb. 28, 1992).
Abraham et al., “A calcium-activated protease from Alzheimer's disease brain cleaves at the N-terminus of the amyloid β-protein”Biochem. Biophys. Res. Comm., 174:790-796 (1991).
Ali et al., “More Transgenic Mouse Studies of Alzheimer Amyloid Precursor (APP) Proteins and Derivatives,”Society for Neuroscience Abstracts, 18(2):abstract 616.8, from 22nd annual Meeting in Anaheim, CA Oct. 25-30, 1992.
Allison et al., “Diabetes in transgenic mice resulting from over-expression of class I histocompatibility molecules in pancretic β cells,”Nature, 333:529-533 (1988).
Antal et al., “Animal Models of Alzheimer's, Parkinson's and Huntington's Disease. A Minireview,”Neurobiology, 1(2):101-122 (1993).
Bonadio et al., “Transgenic Mouse Model of the Mild Dominant Form of Osteogenesis Imperfecta,”PNAS, 87:7145-7149 (1990).
Buxbaum et al., “Expression of APP in Brains of Transgenic Mice Containing the Entire Human App,”Gene, 197(2):639-645 (1993).
Cai et al., “Release of excess amyloid beta protein from a mutant amyloid beta protein precursor”Science259:514-516 (Jan. 22, 1993).
Cai et al., “Release of Excess Amyloid β Protein Precursor.”Science, 259:514-516 (1993).
Ceballos-Picot et al., “Neuronal-specific expression of human copper-zinc superoxide dismutase gene in transgenic mice: animal model od gene dosage effects in Down's syndrome,”Brain Research, 552:198-214 (1991).
Chartier-Harlan et al., “Early onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene”Nature, 353:844-846 (1991).
Citron et al., “Mutation of the beta-amyloid precursor protein in familial Alzheimer's Disease increases beta-protein production”Nature, 360:672-674 (Dec. 17, 1992).
Citron et al., “Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production,”Nature, 360:672-674 (1992).
Cotton, R.G.H., “A G to C Transversion in Codon 258 of the α-Subunit of β-Hexosaminidase A in an Infant Tay-sachs Disease Patient,”Human Mutaion, 2:496-497 (1993).
Crawford et al., “Alzheimer's Disease Untangled,”BioEssays, 14(11):727-734 (1992).
Declaration of Dora Games in Opposition to European Patent 730 643.
De Strooper et al., “Study of the Synthesis and Secretion of Normal and Artificial Mutants of Murine Amyloid Precursor Protein (APP): Cleavage osAPP Occurs in a Late Compartment of the Default Secretion Pathway,”J. Cell Biology, 121(2):295-304 (1993).
Dovey et al., “Cells with a familial Alzheimer's disease mutation produce authentic β-peptide,”NeuroReport, 4:1039-1042 (1993).
Epstein et al., “Transgenic mice with increased Cu/Zn-superoxide dismutase activity: Animal model of dosage effects in Down syndrome,”PNAS, 84:8044-8048 (1987).
Erickson, D., “Model Mice, Transgenic animals aid Alzheimer's research,”Scientific American, Sep. 1991.
Esch et al., “Cleavage of amyloid β peptide during constitutive processing of its precursor”Science, 248:1122-1124 (1990).
Estus et al., “Potentially amyloidogenic, carboxyl-terminal derivatives of the amyloid protein precursor”Science, 255:726-728 (1992).
Felsenstein et al., “Transgenic Rat and In-Vitro Studies of β-Amyloid Precursor Protein Processing,” pp. 401-409 fromAlzheimer's and Parkinson's Disease, edited by Hanin, I., Plenum Press, New York, (1995).
Fidani et al., “Screening for mutations in the open reading frame and promoter of the β-amyloid precursor protein gene in familial Alzheimer's disease: identification of a further family with APP717 Val→11e,”Human Molecular Genetics, 1(3):165-168 (1992).
Fisher et al., “Expression of the amyloid precursor protein gene in mouse oocytes and embryos,”PNAS, 88:1779-1782 (1991).
Forss-Petter et al., “Transgenic mice expressing β-galactosidase in mature neurons under neuron-specific enolase promoter control”Neuron, 5:187-197 (1990).
Francis et al., “Animal and Drug Modelling for Alzheimer Synaptic Pathology,”Progress in Neurobiology, 39:517-545 (1992).
Fraser et al., “Biochemistry of Alzheimer's Disease Amyloid Plaques,”Clin. Biochem., 26:339-349 (1993).
Fukamizu et al., “Chimeric Renin-angiotensin System Demonstrates Sustained Increase in Blood Pressure of Transgenic Mice Carrying Both Human Renin and Human Angiotensinogen Genes,”Journal of Biological Chemistry, 268(16):11617-11621 (1993).
Fukuchi et al., “Intestinal β-Amyloidosis in Transgenic Mic
McConlogue Lisa C.
Sinha Sukanto
Zhao Jun
Crouch Deborah
Elan Pharmaceuticals Inc.
Eli Lilly and Company
Townsend and Townsend / and Crew LLP
LandOfFree
Monitoring APP cleavage in transgenic rodents comprising an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monitoring APP cleavage in transgenic rodents comprising an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monitoring APP cleavage in transgenic rodents comprising an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4090705